Repligen

Yahoo Finance • yesterday

Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • 9 days ago

These small cap stocks are poised for a comeback – Palisade Capital’s Dan Veru

[Markets Open After S&P Falls Nearly 4% On Monday] Spencer Platt/Getty Images News Dan Veru, chief investment officer and senior partner at Palisade Capital Management, believes small cap stocks (NYSEARCA:IWM [https://seekingalpha.com/sym... Full story

Yahoo Finance • 2 months ago

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.... Full story

Yahoo Finance • 2 months ago

Repligen partners with Novasign to enhance bioprocessing systems

WALTHAM, Mass. - Repligen Corporation (NASDAQ:RGEN), a bioprocessing company with a market capitalization of $6.9 billion and annual revenue of $650 million, has formed a strategic partnership with Austria-based Novasign to integrate machi... Full story

Yahoo Finance • 2 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership... Full story

Yahoo Finance • 2 months ago

Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market

REPLIGEN CORP (NASDAQ:RGEN [https://www.chartmill.com/stock/quote/RGEN]) Q2 2025 EARNINGS: REVENUE BEATS ESTIMATES, EPS MISSES AMID MARKET REACTION Repligen Corp reported its second-quarter 2025 financial results, delivering mixed perform... Full story

Yahoo Finance • 2 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20% year-over-yearIncreasing revenue guidance to range of $715 to $735 million, which represents... Full story

Yahoo Finance • 2 months ago

Repligen Q2 2025 Earnings Preview

* Repligen (NASDAQ:RGEN [https://seekingalpha.com/symbol/RGEN]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. * The consensus EPS Estimate is $0.39 [https://seekingalpha.com/symbol/RGEN/earning... Full story

Yahoo Finance • 3 months ago

Repligen's 39% decline validates InvestingPro's January 2024 bearish call

When InvestingPro’s Fair Value models identified Repligen Corporation (NASDAQ:RGEN) as significantly overvalued in January 2024, the bioprocessing company was trading at $193.40. Today, after an 18-month period that saw the stock decline b... Full story

Yahoo Finance • 3 months ago

Repligen to Report Second Quarter 2025 Financial Results

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release... Full story

Yahoo Finance • 4 months ago

Repligen's SWOT analysis: bioprocessing leader's stock faces growth challenges

Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing company valued at $7 billion, has been making waves in the biopharmaceutical industry with its innovative products and strategic acquisitions. As the company navigates through a p... Full story

Yahoo Finance • 4 months ago

Barclays initiates Repligen stock with overweight rating on bioprocessing strength

Investing.com - Barclays initiated coverage on Repligen (NASDAQ:RGEN) with an overweight rating and a $150.00 price target on Monday. The research firm cited Repligen’s positioning as a bioprocessing pure-play company, noting the sector’s... Full story

Yahoo Finance • 4 months ago

908 Devices appoints co-founder Christopher Brown to board of directors

BOSTON - 908 Devices Inc. (NASDAQ:MASS), a company specializing in handheld devices for chemical analysis, announced Monday the appointment of Christopher D. Brown, PhD, to its Board of Directors, effective immediately. Brown, a co-founde... Full story

Yahoo Finance • 5 months ago

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Rep... Full story

Yahoo Finance • 5 months ago

Repligen Corporation to Present at William Blair Growth Conference

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual G... Full story

Yahoo Finance • 5 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conf... Full story

Yahoo Finance • 5 months ago

Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Revenue: $169 million for Q1 2025, a 10% increase year-over-year. Organic Revenue Growth: 11% overall, 14% organic non-COVID growth. Adjusted Gross Margin: 53.7%, up nearly 450 basis points from last year. Adjusted Income from Operations:... Full story

Yahoo Finance • 5 months ago

Repligen (RGEN) Q1 Earnings: What To Expect

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for. Repligen met analysts’ revenue expectations last quarter, reporting revenues of $167.5 milli... Full story

Yahoo Finance • 6 months ago

Repligen to Report First Quarter 2025 Financial Results

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press releas... Full story

Yahoo Finance • 6 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team... Full story